The race for speed: Can Europe compete to be a bigger Phase I hub?

Tortoises are out, hares are in. As biotech emerges from the bear market, the ability to generate early clinical data fast becomes a driver of differentiation and value, and first-in-human data rises as the de-risking asset for companies to draw investors and partners. To compete, European biotechs must move faster.

Moreover, for Europe to build its ecosystem, policymakers must adjust to the new reality where not only is China raising the bar for FIH trials, but there is established and growing competition from Australia, South Korea and other countries...